We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $875B
1-Year Est. Return 40.91%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LHC.WS
12351
DELISTED
Leo Holdings Corp. II Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
LHC.WS
$18K ﹤0.01%
208,827
-60,464
-22% -$12.2K
ENJY
12352
DELISTED
Enjoy Technology, Inc. Common Stock
ENJY
$18K ﹤0.01%
83,566
-78,970
-49% -$92.3K
SLAI
12353
CALL
DELISTED
SOLAI Ltd ADS
SLAI
$17K ﹤0.01%
394
-402
-51% -$50.3K
CRBP icon
12354
Corbus Pharmaceuticals
CRBP
$195M
$17K ﹤0.01%
2,299
-80
-3% -$773
DPRO
12355
CALL
Draganfly
DPRO
$182M
$17K ﹤0.01%
748
-1,072
-59% -$33.3K
ENTX icon
12356
Entera Bio
ENTX
$500M
$17K ﹤0.01%
12,657
-2,400
-16% -$5.33K
HSDT icon
12357
Solana Company
HSDT
$99.3M
0
IFBD icon
12358
Infobird
IFBD
$8.68M
$17K ﹤0.01%
9
XMAX
12359
XMAX Inc
XMAX
$577M
$17K ﹤0.01%
+4,677
New +$22.4K
RNAC icon
12360
CALL
Cartesian Therapeutics
RNAC
$267M
$17K ﹤0.01%
433
+76
+21% +$2.25K
SWVLW icon
12361
Swvl Holdings Corp Warrant
SWVLW
$17K ﹤0.01%
+32,377
New +$16K
AMBR
12362
CALL
Amber International Holding Ltd
AMBR
$124M
$17K ﹤0.01%
2,490
+220
+10% +$1.82K
DGXX
12363
Digi Power X Inc
DGXX
$391M
$17K ﹤0.01%
+16,213
New +$33.6K
VCNX
12364
CALL
DELISTED
Vaccinex, Inc. Common Stock
VCNX
$17K ﹤0.01%
75
-42
-36% -$10.7K
LCAAW
12365
DELISTED
L Catterton Asia Acquisition Corp Warrant
LCAAW
$17K ﹤0.01%
166,666
-100
-0.1% -$26
HEXO
12366
PUT
DELISTED
HEXO Corp. Common Shares
HEXO
$17K ﹤0.01%
5,671
-2,222
-28% -$10.6K
APTX
12367
CALL
DELISTED
Aptinyx Inc. Common Stock
APTX
$17K ﹤0.01%
30,900
+13,600
+79% +$10.9K
ITQRW
12368
DELISTED
Itiquira Acquisition Corp. Warrant
ITQRW
$17K ﹤0.01%
214,176
-41,321
-16% -$7.14K
VIVE
12369
DELISTED
VIVEVE MED INC
VIVE
$17K ﹤0.01%
+25,740
New +$21.9K
EQHA.WS
12370
DELISTED
EQ Health Acquisition Corp. Redeemable Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
EQHA.WS
$17K ﹤0.01%
180,989
-7,471
-4% -$1.55K
GSAQW
12371
DELISTED
Global Synergy Acquisition Corp. Warrant
GSAQW
$17K ﹤0.01%
249,723
-392,775
-61% -$46.3K
NAVB
12372
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$17K ﹤0.01%
24,217
+6,655
+38% +$5.65K
ABTS icon
12373
CALL
Abits Group
ABTS
$4.24M
$16K ﹤0.01%
1,073
-1,407
-57% -$27.7K
APLT
12374
PUT
DELISTED
Applied Therapeutics
APLT
$16K ﹤0.01%
17,200
-9,000
-34% -$14.7K
CCO icon
12375
CALL
Clear Channel Outdoor Holdings
CCO
$1.19B
$16K ﹤0.01%
14,900
-11,100
-43% -$23.3K

Similar funds

Citadel Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Citadel Advisors held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Citadel Advisors's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Citadel Advisors's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Citadel Advisors added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Citadel Advisors's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Citadel Advisors fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Citadel Advisors's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Citadel Advisors opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Citadel Advisors's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.